Nilendu C. Purandare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nilendu C. Purandare has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
Venkatesh Rangarajan
Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
21 shared publicationsArchi Agrawal
Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
17 shared publicationsSneha Shah
Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
16 shared publicationsAmeya Puranik
Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
13 shared publications- Venkatesh Rangarajan
Tata Memorial Hospital
8 shared publications - Archi Agrawal
Department of Nuclear Medicine and Molecular Imaging, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Navi Mumbai, India
6 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6  (Supplement) , 1-2
Radiomics CoxPH Model for Overall Survival Prediction in Head and Neck Cancer
From the 8th International Cancer Congress
- 24 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6  (Supplement) , 1-2
Open AccessRadiomics CoxPH Model for Overall Survival Prediction in Head and Neck Cancer
From the 8th International Cancer Congress
- Open Access
- 1 September 2024
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 39  (5) , 385-388
Serendipitous Detection of Hepatocellular Carcinoma in a Patient Undergoing Staging for Prostate Cancer
Isolated liver metastasis from prostate cancer is exceedingly rare. Prostate-specific membrane antigen–positron emission tomography/computed tomography has become the one-stop shop imaging in prostate cancer, but the uptake is a relatively nonspecific tracer and its expression can be seen in a plethora of nonprostatic solid tumors. We report one such example of an oligometastatic prostate cancer who presented with an isolated liver lesion which turned out to be an incidental hepatocellular carcinoma, thus representing a potentially unique diagnostic challenge.
- 1 September 2024
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 39  (5) , 385-388
Open AccessSerendipitous Detection of Hepatocellular Carcinoma in a Patient Undergoing Staging for Prostate Cancer
Isolated liver metastasis from prostate cancer is exceedingly rare. Prostate-specific membrane antigen–positron emission tomography/computed tomography has become the one-stop shop imaging in prostate cancer, but the uptake is a relatively nonspecific tracer and its expression can be seen in a plethora of nonprostatic solid tumors. We report one such example of an oligometastatic prostate cancer who presented with an isolated liver lesion which turned out to be an incidental hepatocellular carcinoma, thus representing a potentially unique diagnostic challenge.
- 1 January 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 6  (1) , e230075
Post–Renal Transplant Lymphoproliferative Disorder
- 1 January 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 6  (1) , e230075
Post–Renal Transplant Lymphoproliferative Disorder
- 17 April 2023
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48  (7) , e332-e333
FAPI PET Positivity in Fibrolamellar Hepatocellular Carcinoma
Fibrolamellar hepatocellular carcinoma (HCC) is a variant of HCC. It is a malignant tumor, but its imaging features often overlap focal nodular hyperplasia, which is a benign entity. FDG PET/CT is also not much help in these cases because both lesions do not concentrate FDG. We present one such case of fibrolamellar HCC with FAPI PET/CT positivity.
- 17 April 2023
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48  (7) , e332-e333
FAPI PET Positivity in Fibrolamellar Hepatocellular Carcinoma
Fibrolamellar hepatocellular carcinoma (HCC) is a variant of HCC. It is a malignant tumor, but its imaging features often overlap focal nodular hyperplasia, which is a benign entity. FDG PET/CT is also not much help in these cases because both lesions do not concentrate FDG. We present one such case of fibrolamellar HCC with FAPI PET/CT positivity.
- Open Access
- 1 January 2023
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 38  (1) , 84-86
Demonstration of Multiple Metastatic Sites by Positron Emission Tomography/Computed Tomography in a Rare Case of Epithelioid Angiosarcoma of the Scalp
Epithelioid angiosarcoma is a rare subtype of angiosarcoma, with metastases occurring in more than 50% of cases and the lung is the most organ which is involved. Whole-body fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has demonstrated its clinical utility in the early detection of metastases in angiosarcoma. It is helpful to differentiate between benign lesions with low FDG uptake as compared to malignancies with high FDG avidity. Here, we present a rare case of a young man with epithelioid angiosarcoma, in which FDG PET/CT has demonstrated metastatic sites (especially lung metastases).
- 1 January 2023
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 38  (1) , 84-86
Open AccessDemonstration of Multiple Metastatic Sites by Positron Emission Tomography/Computed Tomography in a Rare Case of Epithelioid Angiosarcoma of the Scalp
Epithelioid angiosarcoma is a rare subtype of angiosarcoma, with metastases occurring in more than 50% of cases and the lung is the most organ which is involved. Whole-body fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has demonstrated its clinical utility in the early detection of metastases in angiosarcoma. It is helpful to differentiate between benign lesions with low FDG uptake as compared to malignancies with high FDG avidity. Here, we present a rare case of a young man with epithelioid angiosarcoma, in which FDG PET/CT has demonstrated metastatic sites (especially lung metastases).
- 27 October 2022
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50  (3) , 962-963
Unmasking disseminated streptococcal infection: role of FDG PET/CT in diagnosis and assessing response to antibiotic treatment
- 27 October 2022
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50  (3) , 962-963
Unmasking disseminated streptococcal infection: role of FDG PET/CT in diagnosis and assessing response to antibiotic treatment
- 14 October 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48  (1) , e28-e30
Sporadic Cerebellar Hemangioblastoma With Strong SSTR Expression on 68Ga-DOTANOC PET/CT
Sporadic cerebellar hemangioblastomas are rare with majority of these tumors presenting as a part of von Hippel–Lindau syndrome. We demonstrate an unusual case of a symptomatic sporadic cerebellar hemangioblastoma mimicking a meningioma on MRI and 68Ga-DOTANOC PET imaging.
- 14 October 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48  (1) , e28-e30
Sporadic Cerebellar Hemangioblastoma With Strong SSTR Expression on 68Ga-DOTANOC PET/CT
Sporadic cerebellar hemangioblastomas are rare with majority of these tumors presenting as a part of von Hippel–Lindau syndrome. We demonstrate an unusual case of a symptomatic sporadic cerebellar hemangioblastoma mimicking a meningioma on MRI and 68Ga-DOTANOC PET imaging.
- 4 August 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47  (12) , e731-e732
“Hood Sign” in Nuclear Medicine: An Unusual Presentation of Mantle Cell Lymphoma as Detected on FDG PET/CT
Mantle cell lymphoma is a rare and aggressive non-Hodgkin lymphoma with a high propensity for extranodal involvement, typically seen in the liver, marrow, and gastrointestinal system. Being an FDG-avid disease and a sensitive modality for detecting both nodal and extranodal disease, FDG PET/CT is recommended in the workup of mantle cell lymphoma. We present a rare pattern of cutaneous involvement of the head-neck region in a patient with mantle cell lymphoma, which can be described on FDG PET/CT as a “hood sign.”
- 4 August 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47  (12) , e731-e732
“Hood Sign” in Nuclear Medicine: An Unusual Presentation of Mantle Cell Lymphoma as Detected on FDG PET/CT
Mantle cell lymphoma is a rare and aggressive non-Hodgkin lymphoma with a high propensity for extranodal involvement, typically seen in the liver, marrow, and gastrointestinal system. Being an FDG-avid disease and a sensitive modality for detecting both nodal and extranodal disease, FDG PET/CT is recommended in the workup of mantle cell lymphoma. We present a rare pattern of cutaneous involvement of the head-neck region in a patient with mantle cell lymphoma, which can be described on FDG PET/CT as a “hood sign.”
- 12 January 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47  (3) , e311-e312
Sunitinib-Induced Myositis Detected on 18F-FDG PET/CT
Sunitinib is one of the most commonly used multikinase inhibitors for metastatic renal cell carcinoma. Myositis is one of the rarest known adverse effects of sunitinib. Presenting herewith one such case with its relevant imaging findings on FDG PET/CT and ultrasound.
- 12 January 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47  (3) , e311-e312
Sunitinib-Induced Myositis Detected on 18F-FDG PET/CT
Sunitinib is one of the most commonly used multikinase inhibitors for metastatic renal cell carcinoma. Myositis is one of the rarest known adverse effects of sunitinib. Presenting herewith one such case with its relevant imaging findings on FDG PET/CT and ultrasound.
- Open Access
- 1 October 2021
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 36  (4) , 357-361
Incidentally Detected COVID-19 Lung Changes during Oncologic Fluorodeoxyglucose Positron Emission Tomography-Computerized Tomography Studies
Objective: The objective is to evaluate incidental detection of COVID-19 lung involvement in asymptomatic individuals who undergo fluorodeoxyglucose (FDG) positron emission tomography-computerized tomography (PET/CT) scans for oncologic indications. Patients and Methods: The study was conducted in a tertiary care oncology hospital and included patients who were asymptomatic for COVID-19 infection and underwent FDG PET/CT scans for standard oncologic indications between April 15, 2020, and September 30, 2020. Patients who showed CO-RADS category 4/5 changes (high level of suspicion) on the CT chest component of the PET/CT study were considered for analysis. CT severity score, presence of FDG uptake, and maximum standardized uptake value of FDG avid lung involvement were noted and correlated with reverse transcriptase-polymerase chain reaction (RT-PCR) test. Results: 1982 PET/CT scans were performed, 78 (3.9%) patients showed lung changes with high degree of suspicion of COVID-19 pneumonia (CO-RADS 4/5). Hematolymphoid and head-neck cancer were the most common tumor types (23%), and restaging/response evaluation was the most common PET/CT indication. Of the patients who underwent RT-PCR testing, 70% showed a positive result. The mean CT severity score was 6 (standard deviation 5.9) with no significant difference seen between the RT-PCR positive and negative groups. FDG avidity in lung lesions was noted in 41 out 57 (72%) patients. A significant correlation was seen between the RT-PCR positivity and FDG uptake in lung lesions. Conclusion: A small but significant proportion of patients undergoing routine oncologic PET/CT scans showed incidental COVID-19 lung involvement. Lung involvement in these asymptomatic patients showed a low CT severity score in all patients and FDG avidity in majority. Timely detection of such incidental cases can initiate further confirmatory RT-PCR testing and isolation measures that not only influence patient's cancer treatment protocols but also have a larger community impact of limiting the spread of infection.
- 1 October 2021
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 36  (4) , 357-361
Open AccessIncidentally Detected COVID-19 Lung Changes during Oncologic Fluorodeoxyglucose Positron Emission Tomography-Computerized Tomography Studies
Objective: The objective is to evaluate incidental detection of COVID-19 lung involvement in asymptomatic individuals who undergo fluorodeoxyglucose (FDG) positron emission tomography-computerized tomography (PET/CT) scans for oncologic indications. Patients and Methods: The study was conducted in a tertiary care oncology hospital and included patients who were asymptomatic for COVID-19 infection and underwent FDG PET/CT scans for standard oncologic indications between April 15, 2020, and September 30, 2020. Patients who showed CO-RADS category 4/5 changes (high level of suspicion) on the CT chest component of the PET/CT study were considered for analysis. CT severity score, presence of FDG uptake, and maximum standardized uptake value of FDG avid lung involvement were noted and correlated with reverse transcriptase-polymerase chain reaction (RT-PCR) test. Results: 1982 PET/CT scans were performed, 78 (3.9%) patients showed lung changes with high degree of suspicion of COVID-19 pneumonia (CO-RADS 4/5). Hematolymphoid and head-neck cancer were the most common tumor types (23%), and restaging/response evaluation was the most common PET/CT indication. Of the patients who underwent RT-PCR testing, 70% showed a positive result. The mean CT severity score was 6 (standard deviation 5.9) with no significant difference seen between the RT-PCR positive and negative groups. FDG avidity in lung lesions was noted in 41 out 57 (72%) patients. A significant correlation was seen between the RT-PCR positivity and FDG uptake in lung lesions. Conclusion: A small but significant proportion of patients undergoing routine oncologic PET/CT scans showed incidental COVID-19 lung involvement. Lung involvement in these asymptomatic patients showed a low CT severity score in all patients and FDG avidity in majority. Timely detection of such incidental cases can initiate further confirmatory RT-PCR testing and isolation measures that not only influence patient's cancer treatment protocols but also have a larger community impact of limiting the spread of infection.